

ECNP
Research & Scholarship
Foundation
Annual Report 2024

ECNP Research and Scholarship Foundation

Annual Report 2024

1. About ECNP R&S	3
Objectives	3
Board	3
2. Activities 2024	4
Scientific and educational meetings	4
Awards	4
Other major initiatives	5
3. Financial Overview	6
Financial statements	6
4. Future Outlook	8



The Stichting ECNP Research and Scholarship Foundation is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

1. About ECNP R&S

The ECNP Research and Scholarship Foundation (ECNP R&S) is an independent foundation that exists to promote high-quality experimental and clinical research and education in applied and translational neuroscience, with a view to stimulating the development of better treatments for those suffering disorders of the brain.

The object of the Foundation is to create a framework for the organisation of the annual congresses of ECNP. It is a non-profit making body.

Address:	Daltonlaan 400, 3584 BK Utrecht, The Netherlands
E-mail:	secretariat@ecnp.eu
Website:	https://www.ecnp.eu
RSIN:	807967087
Dutch Chamber of Commerce number:	41215196
Dutch TAX number:	NL807967087B01
ANBI:	The Stichting ECNP Research and Scholarship Foundation is a public-interest-serving entity (<i>algemeen nut beogende instelling</i> – ANBI) under Dutch tax law.

Objectives

ECNP R&S is an independent foundation that exists to promote high-quality experimental and clinical research and education in applied and translational neuroscience, with a view to stimulating the development of better treatments for those suffering disorders of the brain.

The object of the Foundation is to create a framework for the organisation of the annual congresses of ECNP. It is a non-profit making body.

Board

Martien Kas
President
The Netherlands

Brenda Penninx
Treasurer
The Netherlands

Suzanne Dickson
Secretary
Sweden

The members of the board receive no remuneration for their role.

Alexander Schubert
Executive Director
The Netherlands

2. Activities 2024

To execute its mission to support European applied and translational neuroscience, ECNP R&S performs a number of activities annually, focusing especially on stimulating research, sponsoring education and raising awareness.

In 2024 the following programmes were delivered:

Scientific and educational meetings

- **ECNP Workshop for Early Career Scientists in Europe**

14-17 March 2024 – Nice, France

The Workshop offers 100 European early career scientists three days of intense interaction with research leaders discussing the latest advances and perspectives in translational neuroscience.

- **ECNP New Frontiers Meeting: A consensus roadmap for a new diagnostic framework for mental disorders**

17-18 March 2024 – Nice, France

A unique platform for focused, high-level exchange between scientists, industry leaders and regulators at the intersection of research science and new treatment development. The 2024 meeting explored how the new pathways neurobiology is opening to precision diagnostics have the potential to transform neuropsychiatric treatment science.

- **ECNP Workshop on Clinical Research Methods**

20-22 November 2024 – Barcelona, Spain

The Workshop offers 50 European early career scientists three days of training on research methodology and critical approaches to the scientific literature for early career scientists. .

Awards

- **ECNP Downloads Prize**

Awarded to the most-downloaded research paper in the ECNP journal, *Neuroscience Applied* (NSA) in the preceding two years, the award recognises and encourages impactful original research.

Winner 2024: Lea J. Mertens, Germany, et al., 'Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design,' *Neuroscience Applied* in the preceding two years. *Neuroscience Applied* 1 (2022) 100104.

- **ECNP Negative Results Prize**

Awarded to papers that have made exceptional contributions to CNS treatment science by publishing clinical research with negative findings.

The Best Negative Data Prize in Preclinical Neuroscience is planned for 2026, the next Best Negative Data Prize in Clinical Neuroscience for 2027.

Other major initiatives

- **Neuroscience-based Nomenclature (NbN)**

This international collaborative venture, led by ECNP, is working to develop a new nomenclature for psychotropic medications grounded in the latest advances in brain science. Unique in its aims and unprecedented in its scope, in 2024 the initiative's NbN app and NbN-ca app for child and adolescent treatments reached over 135,000 downloads worldwide, with translations in French, Spanish and Chinese, and Portuguese and patient-and-family versions in preparation.

- ***Neuroscience Applied***

Owned by ECNP R&S, this fully open-access scientific journal targets the intersection between neuroscience, applications and new treatment horizons, and features original basic, clinical and integrative research with translational relevance for mental health. Focusing especially on neuroscientific approaches to brain disorders, it encompasses mechanisms of disorders, biological, psychological and social treatments, prevention and policies.

- **ECNP Knowledge Hub**

The Knowledge Hub brings together all of ECNP's expanding repertoire of online content to provide a central repository of information, knowledge tools, and learning resources for researchers and clinicians across the spectrum of applied neuroscience. Already featuring educational courses, webinars and podcasts, the Knowledge Hub will be progressively expanded to cover the breadth of information, learning and research needs and use the knowledge and skills of the ECNP community to advance the field.

- **ECNP Roadmap Initiative**

The ECNP Roadmap Initiative was launched to co-ordinate and accelerate efforts to build a new biology-based diagnostic framework for mental disorders that will advance precision diagnostics and facilitate the development of innovative, mechanism-based treatment strategies beyond the current diagnostic boundaries. The initiative seeks to achieve global alignment with all stakeholders on the way forward to better define and measure neuropsychiatric conditions, harmonise methodologies and data sets across the community, and mobilise resources to implement and validate the framework. The initiative was launched at the 2024 ECNP New Frontiers Meeting (see above) and continued at the ECNP Roadmap Meeting on Precision Psychiatry on 20-21 January 2025 in Frankfurt, Germany.

3. Financial Overview

ECNP R&S is funded from donations, in particular from the ECNP Congress Foundations, subsidies and grants, and income from its investment portfolio.

Its policy is at all times to handle its disposable assets in a responsible and sustainable manner, according to strict principles:

- Proactive tax and regulatory compliance
- Strict observance of the requirements of ANBI ('algemeen nut beogende instelling' = public-interest-service entity) status
- Capital preservation
- Budgetary discipline
- Ongoing diversification of the revenue base

To give substance to this, ECNP R&S invests in securities through an established asset manager using a defensive mandate. The goal is to preserve wealth, to ensure it can continue to deliver its activities and perform its public-good function, not to maximise return.

Financial statements

Balance sheet as at 31 December 2024

(after appropriation of profit/losses)

	31-12-2024		31-12-2023	
	€	€	€	€
ASSETS				
FIXED ASSETS				
Financial fixed assets				
Securities		11,018,368		11,018,368
CURRENT ASSETS				
Accounts receivable				
Debtors	345,938		1,484	
Amounts owed by congress foundations	254,136		337,774	
Taxes	10,106		1,961	
Other accounts receivables	142,208		49,054	
		752,388		390,273
Bank deposits		1,819,159		2,481,951
		2,571,547		2,872,224
		<u>13,589,915</u>		<u>13,890,592</u>

	31-12-2024		31-12-2023	
	€	€	€	€
EQUITY AND LIABILITIES				
EQUITY AND FUNDS				
Other reserves		13,191,696		13,796,336
CURRENT LIABILITIES				
Trade creditors	34,398		14,612	
Other liabilities	363,821		79,644	
		398,219		94,256
		<u>13,589,915</u>		<u>13,890,592</u>

Statement of income and expenditure 2024

	Balance 2024	Balance 2023
	€	€
Income		
Proceeds fundraising	992,772	1,090,827
Journal Neuroscience Applied	20,703	20,853
Neuroscience-based Nomenclature	16,689	24,805
New Frontiers	86,425	-
Interest and similar income	51,387	15,580
Total income	<u>1,167,976</u>	<u>1,152,065</u>
Expenses		
Administration	365,396	374,038
Meetings	261,887	308,697
Journal Neuroscience Applied	53,590	23,000
Neuroscience-based Nomenclature	28,050	64,297
Other expenses	59,067	16,821
Donations	1,000,000	-
Other activities	2,301	-
Total expenses	<u>1,770,291</u>	<u>786,853</u>
Balance before financial expense	<u>-602,315</u>	<u>365,212</u>
Interest and similar charges	-2,324	-1,715
Net result	<u>-604,639</u>	<u>363,497</u>
Appropriation of result		
Other reserves	<u>-604,639</u>	<u>363,497</u>

4. Future Outlook

The ongoing review of ECNP R&S's purpose and strategy continues, as the organisation reviews its mission, where the most impactful contributions can be made, and how relevance and long-term (economic) viability can be assured. Specific issues include:

- How the landscape of European brain science is changing and how ECNP's programmes and activities should adapt to these changes.
- How technology is reshaping the ways in which science is generated, disseminated and consumed, and how ECNP should respond.
- How the organisation's activities can meet the scale of the need they are designed to serve and achieve an impact commensurate with the organisation's mission.
- How the organisation can fulfil its social obligation to reduce its carbon footprint and contribute to environmental preservation.

Plans are being developed to effect change and renewal in all of these areas and equip the organisation with the structures and systems necessary to meet the next decades of its existence. Flagship investments include the Knowledge Hub, a full-scale learning management system (LMS) and content library to expand the scale and reach of ECNP's educational activities and make available its significant store of scientific and learning materials.

